Cu2LCl2(H2O)

[Cu₂LCl₂(H₂O)] (compound 1) (0.5-25 μM; 48 h) potently inhibits proliferation of HCT-116, SW-480, HepG-2, and MCF-7 human tumor cells with IC₅₀ values ranging from 0.68-1.94 μM after 48 h, while exhibiting high selectivity for colon cancer cells and moderate selectivity for liver cancer cells over normal human cells^[1].
[Cu₂LCl₂(H₂O)] (1-25 μM; 24 h) induces dose-dependent apoptosis in HCT-116 and MCF-7 human tumor cells after 24 h of treatment, with a more pronounced effect in HCT-116 cells^[1].
[Cu₂LCl₂(H₂O)] (1-10 μM; 12 h) induces dose-dependent accumulation of ubiquitinated proteins in HCT-116 and MCF-7 human tumor cells after 12 h of treatment at 1-10 μM, confirming functional proteasome inhibition^[1].
[Cu₂LCl₂(H₂O)] (1-25 μM; 12 h) modulates proteasome-related signaling pathways in HCT-116 human colon cancer cells after 12 h of treatment, increasing IκBα, p21, and Bax levels while decreasing NF-κB, Bcl-2, and E2F1 levels to induce apoptosis and cell cycle arrest^[1].
[Cu₂LCl₂(H₂O)] (1-25 μM; 12 h) inhibits PTP1B and TCPTP expression and activity in MCF-7 human breast cancer cells after 12 h of treatment, increasing phosphorylation of their downstream substrates to suppress tumor cell proliferation and induce apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.